GlassScriptPhysician profile
Jeffrey J Stein
NPI 1003818287
$1,544.75
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,533 · 2022: $12.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $300.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $281.97 | 2021-2022 | |
| Amarin Pharma, INC. | $189.51 | 2021 | |
| Sanofi-Aventis U.S. LLC | $169.44 | 2021 | |
| Merck Sharp & Dohme LLC | $114.74 | 2021 | |
| Janssen Pharmaceuticals, INC | $113.26 | 2021 | |
| Pfizer INC. | $90.55 | 2021 | |
| Esperion Therapeutics, INC. | $80.46 | 2021 | |
| Amgen INC. | $37.36 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $36.17 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.40 | 2021 | |
| Arbor Pharmaceuticals, INC. | $26.58 | 2021 | |
| Novo Nordisk INC | $20.13 | 2021 | |
| Tactile Systems Technology INC | $15.77 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.53 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $13.20 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.68 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.